REGENXBIO Inc.
No SEC Form 4 filings for $RGNX in the last 30 days.
See all $RGNX insider activity →H.C. Wainwright cut its Regenxbio (NASDAQ:RGNX) price target to $23 from $26 and kept a Buy rating after Regenxbio completed a common stock offering in July 2026. The firm cited Q2 2026 revenue of $108.0 million and net income of $22.7 million ($0.43/share), plus AbbVie’s $100 million milestone. Regenxbio plans a rolling BLA module for RGX-202 in Q3 2026, targeting accelerated approval in H2 2027.
Investing.com’s Wall Street analyst recap says Wolfe downgraded Fair Isaac (FICO) to Peer Perform, Jefferies cut Best Buy (BBY) to Hold, and BofA downgraded Vale (VALE) to Neutral, citing weaker iron ore margins and an 11% lower $16 target. It also covers WTTR and RGNX downgrades and targets.
Simply Wall St reports REGENXBIO (RGNX) fell about 5% to $10.72 after Q2 results. The company reported Q2 revenue of about $108.0 million versus $21.4 million a year earlier, net income of $22.7 million versus a $70.9 million loss, and basic EPS of about $0.43. The article cites an extended cash runway supported by AbbVie funding and an equity raise, while noting ongoing regulatory and safety risks.
Over the past 7 days, alphai's AI scored 1 news story mentioning RGNX (REGENXBIO Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent RGNX coverage spans financial news, earnings and market movers.
The note is a sell-side valuation reset tied to dilution from the July offering, plus ongoing catalyst timing around the Duchenne rolling BLA module.
The downgrade emphasizes binary regulatory risk and low visibility, which can limit risk appetite even with pipeline optionality.
Despite an earnings beat and longer liquidity, the stock drop signals investors are still discounting binary gene-therapy regulatory and safety risk.
RBC says Regenxbio is on track for Duchenne approval as new data strengthens the case, according to the bank. Separately, Barclays downgraded REGENXBIO to Equalweight from Overweight and set a $12 price target, according to the report. The stock was trading around $10.72 at market close.
Near-term catalysts cluster in 2H 2026 to 1H 2027, anchored by BLA timing and pivotal wet AMD topline expectations.
alphai scores every news story that mentions RGNX with an AI model for sentiment and relevance, and aggregates insider trades from REGENXBIO Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
H.C. Wainwright cut its Regenxbio (NASDAQ:RGNX) price target to $23 from $26 and kept a Buy rating after Regenxbio completed a common stock offering in July 2026. The firm cited Q2 2026 revenue of $108.0 million and net income of $22.7 million ($0.43/share), plus AbbVie’s $100 million milestone. Regenxbio plans a rolling BLA module for RGX-202 in Q3 2026, targeting accelerated approval in H2 2027.
4 min readInvesting.com’s Wall Street analyst recap says Wolfe downgraded Fair Isaac (FICO) to Peer Perform, Jefferies cut Best Buy (BBY) to Hold, and BofA downgraded Vale (VALE) to Neutral, citing weaker iron ore margins and an 11% lower $16 target. It also covers WTTR and RGNX downgrades and targets.
7 min readSimply Wall St reports REGENXBIO (RGNX) fell about 5% to $10.72 after Q2 results. The company reported Q2 revenue of about $108.0 million versus $21.4 million a year earlier, net income of $22.7 million versus a $70.9 million loss, and basic EPS of about $0.43. The article cites an extended cash runway supported by AbbVie funding and an equity raise, while noting ongoing regulatory and safety risks.
6 min readRBC says Regenxbio is on track for Duchenne approval as new data strengthens the case, according to the bank. Separately, Barclays downgraded REGENXBIO to Equalweight from Overweight and set a $12 price target, according to the report. The stock was trading around $10.72 at market close.
2 min readREGENXBIO (Nasdaq: RGNX) reported Q2 2026 results and pipeline updates. It said its Phase III AFFINITY DUCHENNE trial met its primary endpoint (p<0.0001) and it dosed the first patient in the Phase IIb/III NAAVIGATE diabetic retinopathy study. The FDA reaffirmed the path for RGX-121 BLA resubmission in Q3 2026. Cash was $105.5m at June 30, 2026, with pro forma ~$313m after July funding.
7 min readREGENXBIO Inc. (RGNX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 rgnx-ex99_1.htm EX-99.1 EX-99.1 EXHIBIT 99.1 REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights • RGX-202 BLA submission for Duchenne muscular dystrophy on track for Q3 2026 initiation, with potential accelerated approval in 2H 2027 • Lon
6 min readREGENXBIO Inc. (Nasdaq: RGNX) said it will hold a conference call on Aug. 6 at 8:00 a.m. ET to discuss its second-quarter 2026 financial results for the period ended June 30, 2026, and operational highlights. A webcast replay will be posted on its investor website shortly after the call.
2 min readThe Russell 2000 stayed near 3,000 with little movement, while seven small-cap stocks gained at least 28% in four sessions. The article cites July surges for Orthofix (OFIX) on CMS reimbursement reversal, REGENXBIO (RGNX) on FDA resubmission alignment and AbbVie milestone, Verastem (VSTM) on short-squeeze setup, ADC Therapeutics (ADCT) rebound, Sable Offshore (SOC) refinancing, Rapid7 (RPD) takeover speculation, and Crinetics (CRNX) surge toward an offer price.
7 min readREGENXBIO (Nasdaq: RGNX) reported long-term follow-up data for investigational gene therapy surabgene lomparvovec (sura-vec, ABBV-RGX-314) in wet AMD and diabetic retinopathy at ASRS. Wet AMD results showed stable or improved vision through 5 years and reduced anti-VEGF injections, with no new intraocular inflammation. DR data showed 55% >2-step DRSS improvement at 2.5 years. Pivotal topline data with AbbVie expected Q4 2026.
4 min readU.S. stocks fell mid-session, with the Nasdaq down 0.80% and the S&P 500 down 0.51%. Energy shares rose 1.4%. Travelers Companies (TRV) reported Q2 EPS of $10.04 versus $5.38 expected, and sales of $12.153B versus $11.346B expected. Oil rose 4% to $82.06.
3 min read
